会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • A METHOD FOR DECREASING SUPEROXIDE ANION PRODUCTION AND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATIVE STRESS
    • 减少超氧化物阴离子生成和治疗与氧化应激有关的疾病的方法
    • WO02085376A3
    • 2003-03-06
    • PCT/CA0200568
    • 2002-04-19
    • UNIV MONTREALDE CHAMPLAIN JACQUESWU RONGEL MIDAOUI ADIL
    • DE CHAMPLAIN JACQUESWU RONGEL MIDAOUI ADIL
    • A61K31/60A61K31/616A61P3/10A61P5/48A61P9/08A61P9/12A61P29/00A61K31/18A61K31/405
    • A61K31/616A61K31/60
    • The present invention relates to a new method for reducing vascular, cardiac and colonic tissue O2 generation by lowering the NAD(P)H oxidase activity of these tissues in normal and hypertensive subjects using ASA, nimesulide and indomethacin. Although ASA did not show any acute effect in vitro, chronic oral treatment or chronic incubation with ASA significantly lowered the O2 basal or NAD(P)H activated production in aorta and smooth muscle cells from normotensive and hypertensive rats. These effects were dose-dependent and needed more than 3 days to onset in vivo condition. ASA treatment significantly improved the impaired aortic relaxation response to acetylcholine in SHR and significantly attenuated the age-dependent development of hypertension in young SHR. In another model of hypertension and insulin resistance induced by high glucose feeding, which was also found to be associated with a higher production of superoxide anion in tissues from the cardiovascular system, chronic ASA treatment was found to prevent simultaneously the development of hypertension, insulin resistance and the production of superoxide anion. Finally, in another hypertension model induced by the chronic administration of angiotensin II which has the property to activate NAD(P)H oxidase and to enhance the superoxide production in vessels, the concomitant treatment with ASA was also found to simultaneously prevent the development of hypertension and the enhanced superoxide anion production.
    • 本发明涉及一种通过使用ASA,尼美舒利和吲哚美辛降低正常和高血压受试者中这些组织的NAD(P)H氧化酶活性来减少血管,心脏和结肠组织O 2代的新方法。 虽然ASA在体外没有显示任何急性作用,但慢性口服治疗或与ASA的慢性温育显着降低了来自正常血压和高血压大鼠的主动脉和平滑肌细胞中的O2基础或NAD(P)H活化产生。 这些作用是剂量依赖性的,需要超过3天的体内发病。 ASA治疗显着改善SHR中乙酰胆碱受损的主动脉松弛反应,并显着减轻年轻SHR中高血压的年龄依赖性发展。 在高葡萄糖喂养诱导的高血压和胰岛素抵抗的另一模型中,也发现与心血管系统组织中超氧化物阴离子的产生量相关,慢性ASA治疗可以预防同时发生高血压,胰岛素抵抗 并产生超氧阴离子。 最后,在慢性给予血管紧张素II诱导的高血压模型中,其具有激活NAD(P)H氧化酶的性质并增强血管中的超氧化物产生,同时也发现ASA伴随治疗同时预防高血压发展 并增强超氧阴离子的生成。